DSpace JSPUI
DSpace preserves and enables easy and open access to all types of digital content including text, images, moving images, mpegs and data sets
Learn More
Please use this identifier to cite or link to this item:
http://localhost:8080/xmlui/handle/123456789/9146| Title: | Efficacy and safety of anti-interleukin-5 therapy in patients with chronic obstructive pulmonary disease: A meta-analysis of randomized, controlled trials |
| Authors: | Lan, Shao-Huan Lai, Chih-Cheng Chang, Shen-Peng Hsu, Chun-Chun Chen, Cheng-Hsin Wang, Ya-Hui |
| Keywords: | COPD; Anti-IL-5; Mepolizumab; Benralizumab; Eosinophil |
| Issue Date: | 1-Feb-2022 |
| Publisher: | Elsevier Taiwan LLC |
| Abstract: | Abstract Background: Anti-interleukin-5 (IL-5) therapy has been proposed as a novel treatment option for patients with chronic obstructive pulmonary disease (COPD). However, its efficacy for preventing COPD exacerbation remains unclear. Methods: A literature review was conducted to August 26th 2019. Only randomized controlled trials (RCTs) that investigated the clinical efficacy and adverse effects of anti-IL-5 therapy were included in the meta-analysis. The primary outcome was the risk of COPD exacerbation. |
| URI: | http://localhost:8080/xmlui/handle/123456789/9146 |
| ISSN: | 1684-1182 |
| Appears in Collections: | VOL 55 NO 1 2022 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.